<DOC>
	<DOCNO>NCT02360956</DOCNO>
	<brief_summary>The purpose study determine whether olmesartan medoxomil effective treatment coronary atherosclerosis progression epicardial adipose tissue ( EAT ) volume reduction patient coronary atherosclerosis detect coronary CT angiography ( CCTA ) .</brief_summary>
	<brief_title>Efficacy Study Olmesartan Medoxomil Coronary Atherosclerosis Epicardial Adipose Tissue ( EAT )</brief_title>
	<detailed_description>Epicardial adipose tissue ( EAT ) directly deposit around pericardium coronary artery . By mean paracrine action , generate various kind cytokine , inflammatory factor free fatty acid , affect state coronary endothelial function , inflammation oxidative stress , finally aggravate progression coronary atherosclerosis . In recent year , clinical study show EAT newly discover independent risk factor coronary atherosclerosis.Studies confirm olmesartan medoxomil improve endothelial function , resist thrombosis , improve tissue reconstruction , resist oxidative stress achieve atherosclerosis resistant . Latest research show olmesartan medoxomil well inhibit rat epididymal adipose cell hypertrophy inflammatory reaction . Coronary CT angiography ( CCTA ) emerge noninvasive imaging method analysis coronary atherosclerosis . The purpose study determine whether olmesartan medoxomil effective treatment coronary atherosclerosis progression EAT volume reduction patient coronary atherosclerosis detect CCTA .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>coronary artery stenosis 30 % 70 % determine CCTA essential hypertension patient rest diastolic blood pressure ( DBP ) 90 110 mmHg type A B coronary artery vascular lesion secondary hypertension coronary artery stenosis le 30 % great 70 % determine CCTA contraindication treatment olmesartan medoxomil ( allergy , glaucoma , digestive ulcer , currently take phosphodiesterase5 inhibitor ) rest systolic blood pressure ( SBP ) ＞ 200 mmHg rest diastolic blood pressure ( DBP ) ＞ 110 mmHg Severe calcification , distortion type C coronary artery vascular lesion pregnancy unwillingness inability provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Olmesartan medoxomil</keyword>
	<keyword>Epicardial adipose tissue</keyword>
	<keyword>Multidetector Computed Tomography</keyword>
</DOC>